Skip to Content

Moderna Inc

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Moderna Earnings: Progress With Influenza and Rare Disease Programs Supports Our $266 FVE

We’re maintaining our $266 fair value estimate for Moderna following first-quarter results that keep the firm on pace with our expectations for the full year. Covid vaccine revenue of $1.8 billion represented a 69% decline from the first quarter of 2022, as Moderna works through prior contracts that have rolled over from 2022. We expect a significant further drop in sales to roughly $200 million in the second quarter before new and existing contracts tied to an updated vaccine for the 2023/2024 season come into play in the second half of the year. Management maintained guidance for more than $5 billion in sales for the full year, and our own forecast stands at $7.4 billion assuming roughly $1.75 billion from a new U.S. contract, to be negotiated in the second or third quarter (using an average $70 net price and 25 million doses, or roughly 25% of a potential 100 million dose market). We think the firm’s lead in mRNA technology and expanding evidence of efficacy across multiple therapeutic areas could support an economic moat, if the firm stays on track to launch several new vaccines over the next few years.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of MRNA so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center